| SEC For   | m 4<br><b>FORM</b>   |              |   |        |   |   |        |      |                                 |               |                    |  |        |   |   |  |                    |  |                                       |
|---|--|--------------|---|--------|---|---|--------|------|---------------------------------|---------------|--------------------|--|--------|---|---|--|--------------------|--|---------------------------------------|
|   | UNITED STATES SECURITIES AND EXCHANGE COMMISSION<br>Washington, D.C. 20549 |              |   |        |   |   |        |      |                                 |               |                    |  |        |   | OMB APPROVAL  |  |                    |  |                                       |
| Section 16. Form 4 or Form 5 obligations may continue. See                                    |  |              |   |        | ed pur  | NT OF CHANGES IN BENEFICIAL OWNER<br>d pursuant to Section 16(a) of the Securities Exchange Act of 1934<br>or Section 30(h) of the Investment Company Act of 1940 |        |      |                                 |               |                    |  |        |   |   | OMB Number: 3<br>Estimated average burden<br>hours per response:   |                    |  | 3235-0287<br>n<br>0.5                 |
| 1. Name and Address of Reporting Person <sup>*</sup><br>Warden Charles M                      |  |              |   |        |   | 2. Issuer Name and Ticker or Trading Symbol<br><u>OCULAR THERAPEUTIX, INC</u> [ OCUL ]  |        |      |                                 |               |                    |  |        |   | 5. Relationship of Reportin<br>(Check all applicable) |  |                    | son(s) to Iss<br>10% Ov  |                                       |
| (Last)  |  |              |   |        |   | 3. Date of Earliest Transaction (Month/Day/Year) Officer   07/24/2024 Officer   |        |      |                                 |               |                    |  |        |   |   | (give title Other (specify below)  |                    |  | specify                               |
| C/O OCULAR THERAPEUTIX, INC.<br>15 CROSBY DRIVE<br>(Street)                                   |  |              |   | -      | 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Indivi<br>Line) |   |        |      |                                 |               |                    |  |        |   |   |  |                    |  |                                       |
| BEDFOI<br>(City)  |  | 1A<br>State) | 01730   Rule 10b5-1(c) Transaction Indication     (Zip)   Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intersatisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. |        |   |   |        |      |                                 |               | at is intended     | d to   |        |   |   |  |                    |  |                                       |
| Table I - Non-Deriva       1. Title of Security (Instr. 3)     2. Transa<br>Date<br>(Month/D) |  |              |   |        | sactior   | ction 2A. Deemed<br>Execution Date,   |        |      |                                 |               |                    |  | (A) or | or 5. Amount of<br>Securities<br>Beneficially<br>Owned Follow<br>Reported |   |  |                    | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4)        |                                       |
| Common Stock 07/24  |  |              |   | 4/202  | /2024   |   |        | Code | v                               | Amount 12,000 | (D)                |  | Price  | Transact<br>(Instr. 3   |   |  | D                  |  |                                       |
|   | Stock  |              | Table II - I  | Deriva | ative   | Secu  |        |      | uired, D                        |               |                    | or Be  | enef   | icially   |   | ,101   |                    |  |                                       |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)   | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security      |              | 3A. Deemed<br>Execution I<br>if any<br>(Month/Day   | Date,  | 4.<br>Transaction<br>Code (Instr<br>8)                                      |   |        |      | 6. Date Expiration<br>(Month/Da | n Date        | •                  | 7. Title and An<br>of Securities<br>Underlying<br>Derivative Sec<br>(Instr. 3 and 4) |        | ecurity   | 8. Price of<br>Derivative<br>Security<br>(Instr. 5)   | 9. Number<br>derivative<br>Securities<br>Beneficial<br>Owned<br>Following<br>Reported<br>Transaction<br>(Instr. 4) | e<br>S<br>Ily<br>I | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | Beneficial<br>Ownership<br>(Instr. 4) |
|   |  |              |   |        | Code  | v   | (A)    | (D)  | Date<br>Exercisat               |               | Expiration<br>Date | Title  |        | Amount<br>or<br>Number<br>of<br>Shares                                    |   |  |                    |  |                                       |
| Stock<br>Option<br>(Right to<br>Buy)  | \$7.91   | 07/24/2024   |   |        | Α   |   | 36,000 |      | (2)                             | (             | )7/23/2034         | Comm<br>Stoc   |        | 36,000  | \$0   | 36,000   | 0                  | D  |                                       |

## Explanation of Responses:

1. On July 24, 2024, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.

2. Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.

| /s/Donald Notman, Attorney-   | 07/20/2024 |
|-------------------------------|------------|
| in-Fact for Charles M. Warden | 07/26/2024 |

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.